Brief: XBiotech In-Licenses Anti-NY-ESO 1 Antibody Targeting Advanced Cancer
02/04/2018 13:15
April 2 (Reuters) - XBiotech Inc XBIT.O :
* 1 ANTIBODY TARGETING ADVANCED CANCER
* 1 MONOCLONAL ANTIBODY, 12D7
* HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT
ATLANTIC AG
Source text for Eikon: ID:nGNEbmfJVm
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke